Eli Lilly is reportedly close to a $2 billion deal with Hong Kong-based Insilico Medicine for exclusive rights to a GLP-1 drug for diabetes, leveraging AI for drug development.
Why it matters
This potential acquisition highlights the growing trend of major pharmaceutical companies investing heavily in AI-driven drug discovery. Insilico Medicine's use of AI in identifying and developing novel therapeutics, like the GLP-1 drug for diabetes, demonstrates the tangible impact of AI on accelerating and improving the efficiency of pharmaceutical R&D, potentially leading to faster patient access to new treatments.
A big drug company might pay $2 billion to get a new diabetes medicine from a startup that uses AI to find drugs. This shows how AI is helping create new medicines faster.
Elon Musk's AI startup xAI has reportedly seen the departure of its last cofounder, Ross Nordeen, bringing the total number of cofounder exits to eleven.
Read on Economic Times Tech →Physical Intelligence is in talks to raise $1 billion at an $11 billion valuation, just four months after its previous funding round.
Read on Economic Times Tech →OpenSnow, a startup, uses government data and its own AI to provide superior snow forecasting for skiers, outperforming larger services.
Read on MIT Technology Review →